Mark Kester

Mark Kester

Professor of Pharmacology and Biomedical Engineering
Director of the NanoSTAR Institute

Ph.D., State University of New York at Buffalo
Postdoc, University of Illinois, Chicago

Department of Pharmacology
Box 800865
Charlottesville, VA 22908


Research Interests

Dr. Kester has research interests that include the design, characterization and validation of nanotechnologies for targeted drug delivery. His laboratory has evaluated nanoliposomes, nanodendrimers and nanocolloids as effective drug delivery vehicles for pharmacological and molecular agents. Recent work focuses on nontoxic nanoscale systemic delivery systems for hydrophobic pro-apoptotic lipids as well as siRNAs that target mutated tumorigenic proteins. Dr. Kester has consulted with, or helped found, several companies that have the license to his "nano Solutions". In addition, Dr.Kester is a co-author of Integrated Pharmacology, published by Elsevier, Ltd., which was just recognized as a "highly commended textbook" by the British Medical Society.

Selected Publications

Adiseshaiah P, Clogston J, McLeland C, Rodriguez J, Potter T, Neun B, Skoczen S, Shanmugavelandy S, Kester M, Stern S, McNeil S. Synergistic combination therapy with nanoliposomal C6-ceramide and vinblastine is associated with autophagy dysfunction in hepatocarcinoma and colorectal cancer models. Cancer letters. 2013;337(2): 254-65. PMID: 23664889 | PMCID: PMC3722309

Barth B, Shanmugavelandy S, Kaiser J, McGovern C, Alt?no?lu E, Haakenson J, Hengst J, Gilius E, Knupp S, Fox T, Smith J, Ritty T, Adair J, Kester M. PhotoImmunoNanoTherapy reveals an anticancer role for sphingosine kinase 2 and dihydrosphingosine-1-phosphate. ACS nano. 2013;7(3): 2132-44. PMID: 23373542 | PMCID: PMC3757127

Barth B, Shanmugavelandy S, Tacelosky D, Kester M, Morad S, Cabot M. Gaucher's disease and cancer: a sphingolipid perspective. Critical reviews in oncogenesis. 2013;18(3): 221-34. PMID: 23510065 | PMCID: PMC3604879

Hankins J, Ward K, Linton S, Barth B, Stahelin R, Fox T, Kester M. Ceramide 1-phosphate mediates endothelial cell invasion via the annexin a2-p11 heterotetrameric protein complex. The Journal of biological chemistry. 2013;288(27): 19726-38. PMID: 23696646 | PMCID: PMC3707677

Morad S, Madigan J, Levin J, Abdelmageed N, Karimi R, Rosenberg D, Kester M, Shanmugavelandy S, Cabot M. Tamoxifen magnifies therapeutic impact of ceramide in human colorectal cancer cells independent of p53. Biochemical pharmacology. 2013;85(8): 1057-65. PMID: 23353700 | PMCID: PMC3604153